论文部分内容阅读
目的评价培哚普利(雅施达)对于减少2型糖尿病肾病患者尿微量白蛋白的疗效。方法 27例2型糖尿病患者,按糖尿病肾痛分期标准,其中Ⅳ期10例,Ⅴ期17例。随机分为治疗组14例,对照组13例。治疗组加用雅施达4 mg,每日1次,对照组原治疗方案不变。共观察8周。每4周测定血肌酐、尿素氮、尿微量白蛋白。结果治疗组血肌酐、尿素氮无明显变化(P>0.05),尿微量白蛋白显著下降(P<0.05)。对照组尿素氯、尿微量白蛋白无明显变化(P>0.05),血肌酐上升(P<0.05)。两组间尿微量白蛋白及血肌酐同期对比,差异有统计学意义(P<0.05)。结论本组研究证实了新一代 ACE 抑制剂—雅施达对于减少2型糖尿病肾病患者白蛋白排泄,改善肾功能的疗效确定。
Objective To evaluate the efficacy of perindopril in reducing urinary albumin in patients with type 2 diabetic nephropathy. Methods Twenty-seven patients with type 2 diabetes mellitus were enrolled in this study. According to the staging criteria of diabetic nephropathy, there were 10 cases in stage Ⅳ and 17 cases in stage Ⅴ. Randomly divided into treatment group 14 cases, control group 13 cases. The treatment group plus Yashida reached 4 mg once daily, the control group unchanged treatment plan. A total of 8 weeks observation. Serum creatinine, urea nitrogen, and urine microalbumin were measured every 4 weeks. Results Serum creatinine and urea nitrogen in the treatment group showed no significant change (P> 0.05), and urine microalbumin decreased significantly (P <0.05). In the control group, urea chloride and urine microalbumin did not change significantly (P> 0.05), serum creatinine increased (P <0.05). Urinary albumin and serum creatinine between the two groups during the same period, the difference was statistically significant (P <0.05). Conclusion This study confirms the efficacy of a new generation ACE inhibitor, Yasida Da, in reducing albumin excretion and improving renal function in patients with type 2 diabetic nephropathy.